
    inability to recruit participants
  
['kidney failure, chronic', 'prediabetic state']
['liraglutide', 'placebo']

        Inclusion Criteria:

          -  End-stage renal disease treated with chronic maintenance dialysis (haemodialysis or
             peritoneal dialysis)

          -  Impaired glucose tolerance (2h plasma glucose ≥ 7,8 and < 11.1 mmol/l following a
             75g-OGTT) and/or impaired fasting glucose (fasting plasma glucose ≥ 6.1 and < 7.0
             mmol/l) evaluated at the screening visit

        Exclusion Criteria:

          -  Diabetes mellitus type 1 or type 2 (diagnose according to WHO criteria)

          -  Chronic pancreatitis / previous acute pancreatitis

          -  Known or suspected hypersensitivity to trial product(s) or related products

          -  Treatment with oral glucocorticoids, calcineurin inhibitors or incretin-based therapy
             which in the Investigator's opinion could interfere with glucose or lipid metabolism
             90 days prior to screening

          -  Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other
             clinically significant disorder, which in the investigator's opinion could interfere
             with the results of the trial

          -  Clinical suspicion of cardiac disease currently investigated

          -  Cardiac disease defined as: decompensated heart failure (NYHA class III-IV) and/or
             diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6
             months

          -  Body mass index (BMI) <20 kg/m2 and/or >50 kg/m2

          -  Females of childbearing potential who are pregnant, breast-feeding, intend to become
             pregnant or are not using adequate contraceptive methods*

          -  Impaired liver function (transaminases > two times upper reference levels)

          -  The receipt of any investigational product 90 days prior to this trial

          -  Known or suspected abuse of alcohol or narcotics

          -  Screening calcitonin ≥ 50 ng/l

          -  Subjects with personal or family history of medullary thyroid carcinoma or a personal
             history of multiple endocrine neoplasia type 2

        Lawfully detained, institutionalised and patients who are unable to give informed consent
        due to physical or mental conditions will not be included.

        * Intrauterine devices and hormonal contraceptives (oral pills, patches, implants, vaginal
        rings, and injections) are considered as adequate contraceptives. Females of childbearing
        potential must use one of these contraceptives throughout the entire study plus 1 week
        after last injection with study medication. Surgical sterile (by bilateral vasectomy,
        tubectomy, hysterectomy or oophorectomy) or postmenopausal (defined as amenorrheic for at
        least one year) female participants are not considered as having a childbearing potential
        and are not required to use contraception.
      